A Phase 1 interventional study of Anastrozole / Levonorgestrel (BAY98-7196) and Gyno-Daktarin in Endometriosis, sponsored by Bayer. Completed at 1 site in Germany. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-24.
Sponsored by Bayer · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Endometriosis by Bayer — none open to participants now, none under way, none of them phase 3. Endometriosis · Bayer.
Among the 27 studies in Endometriosis by Bayer, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2015, is one of 10 in phase 1, and was the 13th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 27 studies in Endometriosis by Bayer is open now. The open studies under Endometriosis, anywhere →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 68 across the 20 interventional studies, 895 across the 7 observational. Of the 27 that completed or were terminated, 3 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Endometriosis by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the pharmacokinetic effect of a vaginally administered antimycotic (miconazole), antibiotic (clindamycin), spermicide (nonoxynol-9) or the concomitant use of tampons during the use of an intravaginal ring releasing anastrozole and levonorgestrel
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Gyno-Daktarin
Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Sobelin vaginal creme
Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Patentex oval
Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Other: Tampon
Drug pages: Anastrozole · Levonorgestrel
Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
400 mg miconazole nitrate per day for 3 consecutive days
100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
75 mg Nonoxynol-9 per day for 3 consecutive days
Also known as: Tampons (3 changes per day) for 3 consecutive days
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups
Time frame: 202-226h
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups
Time frame: 226-298h
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups
Time frame: 226-384h
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group
Time frame: 466-490h
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group
Time frame: 490-562h
Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group
Time frame: 490-648h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups
Time frame: 202-226h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups
Time frame: 226-298h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups
Time frame: 226-384h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group
Time frame: 466-490h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group
Time frame: 490-562h
Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group
Time frame: 490-648h
Maximum observed plasma concentration before co-medication or tampons (Cmax)
Time frame: 490h
Time to reach maximum observed concentration before co-medication or tampons (tmax)
Time frame: 490h
Plasma concentration 28 days after intra-vaginal ring (IVR) insertion (Treatment group D, Day 29) (C(28d))
Time frame: 672h
Plasma concentration 35 days after IVR insertion (Treatment group D, Day 36)(C(35d))
Time frame: 840h
Average concentration in the extended wearing period (Treatment D, Days 29-36 using the same IVR)
Time frame: 672-840h
Terminal half-life associated with the terminal slope after removal of IVR (t1/2)
Time frame: Up to 6 days after IVR removal
Number of participants with adverse events as a measure of safety and tolerability
Time frame: Up to 14 days after IVR removal
Ran from Sep 2015 to primary completion in Mar 2016, 5 months.
Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anastrozole · Levonorgestrel